^
Association details:
| Biomarker: | miR-155 underexpression |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | sunitinib (Multi-tyrosine kinase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib
Excerpt:
...decreased tissue levels of miR-155 and miR-484 as significantly associated with increased time to progression (miR-155: median TTP 5.8 versus 12.8 months, miR-484: median TTP 5.8 versus 8.9 months)….miR-155 and miR-484 are potentially connected with sunitinib resistance and failure of the therapy.
DOI:
https://dx.doi.org/10.1155%2F2015%2F941980